Acetylcholinesterase Inhibitive Activity-Guided Isolation of Two New Alkaloids from Seeds of Peganum Nigellastrum Bunge by an In Vitro TLC- Bioautographic Assay

被引:110
作者
Zheng, Xi-yuan
Zhang, Zi-jia
Chou, Gui-xin
Wu, Tao
Cheng, Xue-mei
Wang, Chang-hong
Wang, Zheng-tao
机构
[1] Shanghai Univ Tradit Chinese Med, Inst Chinese Mat Med, Shanghai 201210, Peoples R China
[2] Shanghai R&D Ctr Standardizat Chinese Med, Shanghai 201210, Peoples R China
关键词
Peganum nigellastrum Bunge; Acetylcholinesterase; TLC-bioautographic assay; Alzheimer's disease; Alkaloid; Nigellastrine I; Nigellastrine II; ALZHEIMERS-DISEASE; BETA-CARBOLINES; HARMALA ALKALOIDS; HARMINE; GALANTHAMINE; DERIVATIVES; BINDING;
D O I
10.1007/s12272-009-1910-x
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Acetylcholinesterase inhibitors (AChEIs) currently form the basis of the newest drugs available for the treatment of Alzheimer's disease. For the aim of screening effective AChEIs, the methanol extracts of the seeds of genus Peganum were found to show significant inhibitory activity of acetylcholinesterase enzyme (AChE) using an in vitro TLC-bioautographic assay. In further studies to seed of P. nigellastrum Bunge, activity-guided fractionation led to the isolation of two new alkaloids nigellastrine I (9) and nigellastrine II (10), and along with eight known alkaloids, vasicinone (1), vasicine (2), harmine (3), deoxyvasicinone (4), deoxyvasicine (5), harmaline (6), harmol (7), harman (8), in which harmol and harman were first isolated from species P. nigellastrum Bunge. As active constituents, all compounds showed good inhibitory activities against AM. The results of in vitro semi-quality TLC-bioautographic assay showed that harmine, harmaline and harmol displayed a similar AChE inhibitive activities comparing to galanthamine. These results indicated that these alkaloids in P. nigellastrum Bunge could be a potent class of AChEIs.
引用
收藏
页码:1245 / 1251
页数:7
相关论文
共 27 条
[1]   CARDIOVASCULAR ACTIONS OF 3 HARMALA ALKALOIDS - HARMINE, HARMALINE, AND HARMALOL [J].
AARONS, DH ;
ROSSI, GV ;
ORZECHOWSKI, RF .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1977, 66 (09) :1244-1248
[2]   STUDY OF THE INVITRO ANTIMICROBIAL ACTIVITY OF HARMINE, HARMALINE AND THEIR DERIVATIVES [J].
AHMAD, A ;
KHAN, KA ;
SULTANA, S ;
SIDDIQUI, BS ;
BEGUM, S ;
FAIZI, S ;
SIDDIQUI, S .
JOURNAL OF ETHNOPHARMACOLOGY, 1992, 35 (03) :289-294
[3]  
AIRAKSINEN MM, 1981, MED BIOL, V59, P21
[4]   POTENTIAL PHARMACOTHERAPY OF ALZHEIMER-DISEASE - A COMPARISON OF VARIOUS FORMS OF PHYSOSTIGMINE ADMINISTRATION [J].
BECKER, R ;
GIACOBINI, E ;
ELBLE, R ;
MCILHANY, M ;
SHERMAN, K .
ACTA NEUROLOGICA SCANDINAVICA, 1988, 77 :19-32
[5]   Alzheimer's disease [J].
Scheltens, Philip ;
De Strooper, Bart ;
Kivipelto, Miia ;
Holstege, Henne ;
Chetelat, Gael ;
Teunissen, Charlotte E. ;
Cummings, Jeffrey ;
van der Flier, Wiesje M. .
LANCET, 2021, 397 (10284) :1577-1590
[6]  
Bores GM, 1996, J PHARMACOL EXP THER, V277, P728
[7]   In vitro activity of the β-carboline alkaloids harmane, harmine, and harmaline toward parasites of the species Leishmania infantum [J].
Di Giorgio, C ;
Delmas, F ;
Ollivier, E ;
Elias, R ;
Balansard, G ;
Timon-David, P .
EXPERIMENTAL PARASITOLOGY, 2004, 106 (3-4) :67-74
[8]  
DUAN J, 1998, ZHONGGUO YAOKE DAXUE, V29, P100
[9]   A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon®) [J].
Forette, F ;
Anand, R ;
Gharabawi, G .
EUROPEAN JOURNAL OF NEUROLOGY, 1999, 6 (04) :423-429
[10]   The cholinergic hypothesis of Alzheimer's disease: a review of progress [J].
Francis, PT ;
Palmer, AM ;
Snape, M ;
Wilcock, GK .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1999, 66 (02) :137-147